Overview

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Deferasirox